Skip to content
Peptide Index.

Tissue repair research

TB-500 review

Why a trial of thymosin beta-4 eye drops cannot validate injectable TB-500 recovery claims.

Selected-source editorial reviewSources checked

Peptide Index is operated by the team behind Peptide Guide, a peptide vendor. Read our disclosure.

Included evidence

Related-molecule trial

What was studied

Adults with dry eye received a thymosin beta-4 ophthalmic formulation, not injectable TB-500.

What the research found

  • The selected trial missed its primary endpoints; some secondary outcomes improved.

Where the evidence stops

  • The tested formulation, route, and condition differ from TB-500 injury-recovery claims.
  • FDA identifies TB-500 as a thymosin beta-4 fragment; it should not be treated as interchangeable with the trial product.

Safety context

FDA describes immune-response and impurity concerns and missing human exposure information for the TB-500 fragment.

Educational information only. This review does not recommend self-treatment or establish that products sold online match a studied formulation. Individual medical decisions belong with a qualified clinician.

Read the sources

These are the documents included in this review. Evidence labels describe this selection; they are not effectiveness or safety scores.

  1. Original research — PubMed abstract

    Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. (opens in a new tab)

  2. FDA safety information

    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (opens in a new tab)

This is a selected-source editorial review, not a systematic review or a claim of medical review. New findings may change the assessment.

Next editorial check due .

How these reviews are prepared